British pharmaceutical company GSK on Wednesday said ... United States surrounding its Zantac heartburn drug. GSK suffered a loss after tax of £58 million ($75 million) in the July-September ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

GSK) soared over 6% after the company announced a settlement of up to $2.2 billion for Zantac lawsuits in the U.S. The settlement addresses 80,000 cases, accounting for 93% of the pending lawsuits ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

GSK has opted to settle a key lawsuit in its defence against claims that its Zantac drug caused cancer, rather than proceed with a jury trial. The company said this morning it had reached a ...

GSK said total sales fell by two per cent in the third quarter Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance and ...

At 4:31 am (0831 GMT), GSK was trading 1.5% higher at £1,642.11. The litigation at the center of this legal battle revolves ...

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen. The ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen.